Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

ESMO Open

Volumn 1, Issue 6, 2016, Pages

  Tabernero, Josep ^a   Vyas, Malvika ^b   Giuliani, Rosa ^c   Arnold, Dirk ^d   Cardoso, Fatima ^e   Casali, Paolo G ^f   Cervantes, Andres ^g   Eggermont, Alexander M M ^h   Eniu, Alexandru ⁱ   Jassem, Jacek ^j   Pentheroudakis, George ^k   Peters, Solange ^l   Rauh, Stefan ^m   Zielinski, Christoph C ⁿ   Stahel, Rolf A ^o   Voest, Emile ^p   Douillard, Jean Yves ^b   McGregor, Keith ^b   Ciardiello, Fortunato ^q  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ESMO HEAD OFFICE   (Switzerland)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d CUF Hospital   (Portugal)

^e CHAMPALIMAUD CLINICAL CENTER   (Portugal)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Hospital Clinic   (Spain)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k UNIVERSITY OF IOANNINA   (Greece)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m Centre Hospitalier Emile Mayrisch   (Luxembourg)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o NETHERLANDS CANCER INSTITUTE   (Netherlands)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Biobetters; Biosimilars; Cancer Treatment; Generics; Health Financial Burden; Non comparable Biosimilars

Indexed keywords

EID: 85019067891     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2016-000142     Document Type: Review

References (29)

1. European Central Bank. https://www.ecb.europa.eu/stats/exchange/ eurofxref/html/eurofxref-graph-usd.en.html (accessed Nov 2016).
2. IMS Institute for Healthcare Informatics. Global oncology trend report: a review of 2015 and outlook to 2020. Parsippany: IMS Institute for Healthcare Informatics, 2016.
3. IMS Institute for Healthcare Informatics. The global use of medicines: outlook through 2017. Parsippany: IMS Institute for Healthcare Informatics, 2013.
4. European Medicines Agency. European public assessment reports.http: //www.ema.europa.eu/ema/index.jsp?mid=WC0b01ac 058001d124&searchType=name&taxonomyPath=&genericsKeyword Search=Submit&searchGenericType=biosimilars&keyword=Enter+ke ywords&alreadyLoaded=true&curl=pages%2Fmedicines%2Flanding %2Feparsearch.jsp&status=Authorised&status=Withdrawn&status= Suspended&status=Refused&treeNumber=&searchTab=searchByAut hType&pageNo=1 (accessed Nov 2016).
5. European Medicines Agency. http://www.ema.europa.eu/docs/en GB/documentlibrary/Pressrelease/2013/06/WC500144941.pdf (accessed Dec 2016).
6. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012;28:1053-8.
7. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring: Food and Drug Administration, 2015.
8. European Medicines Agency. QRD general principles regarding the SmPC information for a generic/hybrid/biosimilar product. London: European Medicines Agency, 2012.
9. European Medicines Agency. Guideline on similar biological medicinal products (revision 1). London: European Medicines Agency, 2014.
10. World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). Geneva, Switzerland: World Health Organization, 2016.
11. United States Food and Drug Administration. Non-proprietary naming of biological products: guidance for industry (Draft Guidance). Silver Spring: United States Food and Drug Administration, 2015.
12. European Medicines Agency. Concept paper on extrapolation of efficacy and safety in medicine development. London: European Medicines Agency, 2013.
13. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: clinical and non-clinical issues. London: European Medicines Agency, 2014.
14. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency, 2005.
15. European Medicines Agency. http://www.ema.europa.eu/ema/index. jsp?curl=pages/regulation/qanda/qandadetail000129.jsp&mid =WC0b01ac0580533e0f (accessed Dec 2016).
16. Niederwieser D, Schmitz S. Biosimilar agents in oncology/ haematology: from approval to practice. Eur J Haematol 2011;86:277-88.
17. Agency for Medicinal Products and Medical Devices of Croatia. http:/ /www.halmed.hr/en/Lijekovi/Informacije-o-lijekovima/Bioloski-i-biosli cni-lijekovi/ (accessed Nov 2016).
18. Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol 2015;8:649-59.
19. European Medicine Agency. Questions and answers on generic medicines. London: European Medicines Agency, 2012.
20. European Commission. Commission directive 2003/63/EC of 25 June 2003 amending directive 2001/83/EC of the european parliament and of the council on the community code relating to medicinal products for human use UK, London: European Commission, 2013.
21. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: clinical and non-clinical issues. London: European Medicines Agency, 2014.
22. European Medicines Agency. Guideline on similar biological products containing biotechnology-derived proteins as active substance: quality issues (revision 1). London: European Medicines Agency, 2012.
23. IMS Institute for Health Informatics. Global medicines Use in 2020: outlook and implications. Parsippany: IMS Institute for Health Informatics, 2015.
24. IMS Institute for Health Informatics. Delivering on the potential of biosimilar medicines. Parsippany: IMS Institute for Health Informatics, 2016.
25. European Medicine Agency. Guideline on similar biological medicinal products. London: European Medicines Agency, 2014.
26. European Medicines Agency. Biosimilar medicinal products. London: European Medicines Agency, 2011.
27. European Medicines Agency. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000585/humanmed000643.jsp&mid=WC0b01ac058001d124(accessed Nov 2016)
28. Quintiles IMS. Biosimilars by region: Asia Pacific. http://www.quintiles.com/microsites/biosimilars-knowledge-connect/biosimilars-by-region/asia-pacific (accessed Nov 2016).
29. Castañeda-Hernández G, Szekanecz Z, Mysler E, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014;81:471-7.